Rewriting the Rules of Medicine with Dr. Ben Ebert

From his roots in Bethesda, Maryland, to leading one of the most prestigious cancer institutions in the world, Dr. Ebert is a true example of intellect, humility, and purpose. Our conversation covered everything from transformative science to leadership, mentorship, and the future of medicine.

A leader shaped by curiosity, mentorship, and mission

Dr. Ebert's path to medicine wasn't preordained. A math major and former juggler at Williams College, he considered architecture before committing to oncology. That curiosity continues to drive his leadership at Dana-Farber, where he manages a $3.5 billion operation and a research budget supported by government grants, private philanthropy, and industry partnerships.

What stands out most about Dr. Ebert is his dedication to mentorship. As he explained, one of the greatest joys in his career is seeing students from his lab grow into leaders in science and medicine across the globe. It's a testament to the culture of excellence and collaboration that defines Dana-Farber.

Building breakthroughs, brick by brick

Dana-Farber is expanding, not just in its research and treatment capabilities but also physically, with a new 300-bed inpatient hospital under construction. As Dr. Ebert shared, the planning and execution of this facility is akin to a commercial real estate development project, an intersection where our worlds align.

In fact, I first connected with Dana-Farber in 1994 when I ran the Boston Marathon on its charity team. Today, the Institute benefits enormously from community events like the Pan-Mass Challenge, which has raised over $1 billion for cancer research. That level of engagement is rare and speaks volumes about the mission and values of Dana-Farber.

Funding the fight: balancing public, private, and philanthropic support

Dr. Ebert broke down the funding model that keeps Dana-Farber at the forefront of cancer research. Roughly one-third of research funding comes from the federal government, another third from philanthropy, and the rest from industry partnerships.

Philanthropic support—often the fastest and most flexible—allows Dana-Farber to launch promising research before grant approvals. Meanwhile, collaboration with biotech and pharma companies accelerates drug development, benefiting patients sooner.

Despite political uncertainty affecting institutions like Harvard, Dana-Farber’s independent governance has helped it remain insulated from funding freezes, though the broader Boston biomedical ecosystem remains a concern.

Collaboration over competition in the fight against cancer

While Dana-Farber competes with other leading institutions like MD Anderson and Memorial Sloan Kettering, Dr. Ebert emphasized the importance of collaboration. Initiatives like Break Through Cancer bring top scientists together across institutions, and many major papers today feature joint authorship and co-patenting, a sign of how deeply integrated research has become.

Even in recruitment, Dana-Farber attracts top talent by fostering an environment where science and clinical care coexist, and where people are driven by purpose as much as compensation.

Innovation on the front lines of care

From immunotherapy and cellular therapy to early detection and AI, Dr. Ebert highlighted how innovation is transforming outcomes. Where once a diagnosis of metastatic melanoma was a death sentence, today nearly half of patients achieve long-term remission thanks to checkpoint inhibitors. Cellular therapies, where a patient’s own T-cells are engineered to fight cancer, are redefining what’s possible in hematologic cancers.

The AI revolution is also well underway. Algorithms are helping interpret imaging, predict protein structures, and optimize drug discovery. Tools like Google’s AlphaFold are now much more than theoretical; they’re reshaping labs like Dr. Ebert’s in real time.

Looking ahead: optimism, early detection, and audacious goals

When asked what the next five years hold, Dr. Ebert was unequivocally optimistic. New modalities once thought impossible—like targeting the KRAS mutation prevalent in pancreatic, colon, and lung cancers—are now producing real clinical results.

He also emphasized the rising importance of early detection. Blood-based cancer screening and AI-driven diagnostics could usher in a new era of interception, where cancers are found earlier and treated more effectively.

Want more?

As host of the Walker Webcast, I have the privilege to converse with fascinating people like Dr. Ben Ebert every week. Subscribe to the Walker Webcast to see our upcoming guests.